Format

Send to

Choose Destination
Leuk Lymphoma. 2018 Aug;59(8):1851-1860. doi: 10.1080/10428194.2017.1403597. Epub 2017 Nov 21.

Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.

Author information

1
a Department of Hematology/Oncology , Fox Chase Cancer Center , Philadelphia , PA , USA.
2
b Department of Biostatistics , University of Arkansas for Medical Sciences , Little Rock , AR , USA.
3
c Department of Oncology, School of Medicine , Johns Hopkins University , Baltimore , MD , USA.
4
d Department of Oncology , Montefiore-Einstein Cancer Center, Montefiore Medical Center , Bronx , NY , USA.
5
e Department of Medicine , Memorial Sloan-Kettering Cancer Center/Weill-Cornell Medical College , New York , NY , USA.

Abstract

Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.

KEYWORDS:

AIDS; HIV; HIV-associated lymphoma; chemotherapy; combination antiretroviral therapy; dose-adjusted EPOCH

PMID:
29160731
PMCID:
PMC5962410
[Available on 2019-08-01]
DOI:
10.1080/10428194.2017.1403597

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center